XRAYS - Making Sense of Cancer Headlines

FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.

XRAYS logo and women

Read the topic that we reviewed this week

STUDY: A low-fat diet may decrease postmenopausal breast cancer deaths

XRAYS Rating
XRAYS study

Research reported at the 2019 annual meeting of the American Society of Clinical Oncology establishes a link between dietary fat intake and its impact on postmenopausal women’s risk of dying from breast cancer. (6/13/19)

Search for reviews by category, keyword or date or browse our recent articles below

Featured Studies and Articles

XRAYS Rating

ARTICLE: A young woman's story of genetic testing and risk-reducing mastectomy

Alejandra Campoverdi comes from a family with three generations of breast cancer. As a former White House aide and active educator in the Latina community, she has openly shared her story of genetic testing, her BRCA2 mutation and her plans for risk-reducing mastectomy at age 39. (6/6/19)

XRAYS Rating

STUDY: FDA approves an immunotherapy treatment for some patients with triple-negative breast cancer

The FDA approved the use of the immunotherapy drug Tecentriq (atezolizumab) in combination with the chemotherapy agent Abraxane (nab-paclitaxel) for certain patients with advanced triple-negative breast cancer.

5/26/19

XRAYS Rating

STUDY: Do Vitamin B supplements alter breast cancer risk for women with BRCA mutations?

Vitamins are an essential part of our diet. Vitamin supplements are often used to improve general health. This study explores how vitamin B supplements may affect breast cancer risk in women with BRCA mutations. (5/17/19)

XRAYS Rating

STUDY: Smart drug shows promising results for treatment of metastatic triple-negative breast cancer

We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is an antibody-drug conjugate, meaning that it combines two different molecules: an antibody that targets certain proteins or tumor markers and delivers SN-38, a chemotherapy drug that can kill tumor cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)

Find older XRAYS studies and articles

By keyword search:

By date range:

FORCE:Facing Our Risk of Cancer Empowered